-
2024Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies, Pathogens and Immunity, 2024, 10 (1), pp.1-11. ⟨10.20411/pai.v10i1.752⟩.
-
2024Levels and functionality of Pacific Islanders’ hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia., PLoS Med 2024 Sep; 21(9): e1004397.
-
2024Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine, International Journal of Infectious Diseases, 2024, 146, pp.107108. ⟨10.1016/j.ijid.2024.107108⟩.
-
2024Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study., Lancet Child Adolesc Health 2024 Aug; (): .
-
2024COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans, JAMA Network Open, 2024, 7 (7), pp.e2419258. ⟨10.1001/jamanetworkopen.2024.19258⟩.
-
2024COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans., JAMA Netw Open 2024 Jul; 7(7): e2419258.
-
2024Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine., Int J Infect Dis 2024 May; 146(): 107108.
-
2024COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022, Eurosurveillance, 2024, 29 (13), pp.2300403. ⟨10.2807/1560-7917.es.2024.29.13.2300403⟩.
-
2024COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022., Euro Surveill 2024 Mar; 29(13): .
-
2024Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024, Eurosurveillance, 2024, 29 (8), ⟨10.2807/1560-7917.es.2024.29.8.2400089⟩.
-
2024Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024., Euro Surveill 2024 Feb; 29(8): .
-
2024Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study, Influenza and Other Respiratory Viruses, 2024, 18 (1), pp.e13243. ⟨10.1111/irv.13243⟩.
-
2024Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study., Influenza Other Respir Viruses 2024 Jan; 18(1): e13243.
-
2023Seasonal and inter‐seasonal RSV activity in the European Region during the COVID‐19 pandemic from autumn 2020 to summer 2022, Influenza and Other Respiratory Viruses, 2023, 17 (11), pp.e13219. ⟨10.1111/irv.13219⟩.
-
2023Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022., Influenza Other Respir Viruses 2023 Nov; 17(11): e13219.
-
2023Investigations into SARS-CoV-2 and other coronaviruses on mink farms in France late in the first year of the COVID-19 pandemic, PLoS ONE, 2023, 18 (8), pp.e0290444. ⟨10.1371/journal.pone.0290444⟩.
-
2023Emergence and evolution of the Omicron SARS-CoV-2 variant in the island of Martinique, Infectious Diseases Now, 2023, 53 (4), pp.104690. ⟨10.1016/j.idnow.2023.104690⟩.
-
2023Emergence and evolution of the Omicron SARS-CoV-2 variant in the island of Martinique., Infect Dis Now 2023 Jun; 53(4): 104690.
-
2023Investigations on SARS-CoV-2 and other coronaviruses in mink farms in France at the end of the first year of COVID-19 pandemic, 2023.
-
2023Investigations on SARS-CoV-2 and other coronaviruses in mink farms in France at the end of the first year of COVID-19 pandemic., bioRxiv 2023 Feb; (): .
-
2023Investigations into SARS-CoV-2 and other coronaviruses on mink farms in France late in the first year of the COVID-19 pandemic., PLoS One 2023 ; 18(8): e0290444.
-
2022Capturing SARS-CoV-2 from patient samples with low viral abundance: a comparative analysis, 2022 12:19274.
-
2021Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France., Lancet Reg Health Eur 2021 Sep; 8(): 100171.
-
2021Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification, PLOS ONE, 16(1), e0243712 - January 2021.
-
2020A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations, Science Translational Medicine, 2020, 12 (559), pp.eabc3103. ⟨10.1126/scitranslmed.abc3103⟩.
-
2020Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification., medRxiv 2020.08.01.20166538.
-
2020Introductions and early spread of SARS-CoV-2 in France, 24 January to 23 March 2020., Euro Surveill. 2020 07; 25(26): .
-
2015Early estimates of 2014/15 seasonal influenza vaccine effectiveness in preventing influenza-like illness in general practice using the screening method in France, Hum Vaccin Immunother 2015 Jul;11(7):1621-5.
-
2015Erratum to: Genetic Adaptation of Influenza A Viruses in Domestic Animals and Their Potential Role in Interspecies Transmission: A Literature Review, Ecohealth 2015 May;.
-
2015Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype, Euro Surveill. 2015;20(4).
-
2015Genetic Adaptation of Influenza A Viruses in Domestic Animals and Their Potential Role in Interspecies Transmission: A Literature Review, Ecohealth 2015 Jan;.
-
2014Influenza at the animal-human interface: a review of the literature for virological evidence of human infection with swine or avian influenza viruses other than A(H5N1), Euro Surveill. 2014;19(18).
-
2013Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility, Lancet Infect Dis 2014 Jan;14(1):50-56.
-
2013Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections–the Fluco French cohort, J. Clin. Virol. 2013 Sep;58(1):114-9.
-
2013First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013, Euro Surveill. 2013;18(24).
-
2013Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission, Lancet 2013 Jun;381(9885):2265-72.
-
2013Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe, J. Clin. Virol. 2013 May;57(1):5-12.
-
2012I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y, PLoS ONE 2012;7(8):e37095.
-
2012Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections, Antiviral Res. 2012 Nov;96(2):130-7.
-
2012HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains, Vaccine 2012 Jul;30(35):5262-9.
-
2012Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France, PLoS ONE 2012;7(3):e33056.
-
2012Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter, Clin. Microbiol. Infect. 2013 Feb;19(2):196-203.
-
2011S-OtrH3N2 viruses: use of sequence data for description of the molecular characteristics of the viruses and their relatedness to previously circulating H3N2 human viruses, Euro Surveill. 2011;16(50):20039.
-
2011Highly heterogeneous temperature sensitivity of 2009 pandemic influenza A(H1N1) viral isolates, northern France, Euro Surveill. 2011 Oct;16(43).
-
2011Surveillance trends of the 2009 influenza A(H1N1) pandemic in Europe, Euro Surveill. 2011;16(26).
-
2011Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes, Vaccine 2011 Aug;29(37):6283-91.
-
2011Monitoring epidemic viral respiratory infections using one-step real-time triplex RT-PCR targeting influenza A and B viruses and respiratory syncytial virus., J Med Virol 2011 Apr; 83(4): 695-701.
-
2010Initial surveillance of 2009 influenza A(H1N1) pandemic in the European Union and European Economic Area, April-September 2009, Euro Surveill. 2010 Dec;15(49).
-
2010Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial, PLoS Med. 2010;7(11):e1000362.
-
2009Molecular epidemiology of clade 1 influenza A viruses (H5N1), southern Indochina peninsula, 2004-2007, Emerging Infect. Dis. 2009 Oct;15(10):1641-4.
-
2009Kinetics of nasopharyngeal shedding of novel H1N1 (swine-like) influenza A virus in an immunocompetent adult under oseltamivir therapy., Clin Microbiol Infect 2009 Dec; 15(12): 1189-91.
-
2009Preliminary analysis of influenza A(H1N1)v individual and aggregated case reports from EU and EFTA countries, Euro Surveill. 2009 Jun;14(23):19238.
-
2009[Glycopeptide-resistant enterococci carriage: Are actual isolation and identification techniques sufficient?], Pathol. Biol. 2011 Jun;59(3):146-50.
-
2009Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season, Emerging Infect. Dis. 2009 Apr;15(4):552-60.
-
2009Guillain-Barré syndrome and influenza virus infection, Clin. Infect. Dis. 2009 Jan;48(1):48-56.
-
2008Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir., PLoS Pathog 2008 Jul; 4(7): e1000103.
-
2007Acute bilateral uveitis associated with an active human herpesvirus-6 infection, J. Infect. 2007 Apr;54(4):e237-40.
-
2006Identification of genotype 1 hepatitis E virus in samples from swine in Cambodia, J. Clin. Microbiol. 2006 Sep;44(9):3440-2.
-
2006Validation of single real-time TaqMan PCR assay for the detection and quantitation of four major genotypes of hepatitis E virus in clinical specimens, J. Med. Virol. 2006 Aug;78(8):1076-82.
-
2005Genetic heterogeneity of hepatitis E virus in Darfur, Sudan, and neighboring Chad, J. Med. Virol. 2005 Dec;77(4):519-21.
-
2004Evidence for hepatitis E virus quasispecies, J. Gen. Virol. 2004 Nov;85(Pt 11):3189-94.
-
2003Interactions of rotavirus VP4 spike protein with the endosomal protein Rab5 and the prenylated Rab acceptor PRA1, J. Virol. 2003 Jun;77(12):7041-7.
-
2002Rafts promote assembly and atypical targeting of a nonenveloped virus, rotavirus, in Caco-2 cells, J. Virol. 2002 May;76(9):4591-602.
-
2001Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic, Appl. Environ. Microbiol. 2001 Apr;67(4):1423-8.